

5

MYPERIOPATH® CLINICAL CONSIDERATIONS


Doe, John A.
Date Of Birth: 00/00/0000
Gender: Male

Sample Information
Accession: 00000001PPT
Specimen: Oral Rinse
Collected: 00/00/0000
00:00



Result: POSITIVE - 5 PATHOGENIC BACTERIA REPORTED ABOVE THRESHOLD
Bacterial Risk: HIGH - Very strong evidence of increased risk for attachment loss

Aa Pg Fn Pi Cs



6

Treatment Considerations

- Office Periodontal Therapy:** Protocols to disrupt biofilm and reduce pathogens.
- Systemic Antibiotic Option to Augment Therapy at Clinician's Discretion:**

Clinician to determine if local antimicrobials (e.g. Chlorhexidine) and/or local antibiotics (e.g. Arestin) are sufficient to resolve infection.

Published guidelines suggest (subject to allergy, drug interaction, and other medical considerations) the following as a possible adjunct to treatment based on patient's bacterial profile: Amoxicillin 500 mg tid 8 days and Metronidazole 500 mg bid 8 days.

Note: Doctor is responsible for patient therapy. Complete dental and medical history (e.g. pregnancy, diabetes, immuno-suppression, other patient medications) should be considered when prescribing. Antibiotics may impact other medications (e.g. birth control pills) and may have adverse side effects.

7

- Home Care:** Office recommended procedures to daily disrupt biofilm and reduce pathogens.
- Reassessment:** Compare clinical signs and bacterial levels pre- and post-treatment.
- A 2nd sample should be collected six to eight weeks post-therapy.

Additional Risk Factors

Clinical	Diagnostic	Medical
BOP <input type="checkbox"/>	Localized <input type="checkbox"/>	Family History of PD <input type="checkbox"/>
Inflammation/Swelling <input checked="" type="checkbox"/>	Generalized <input checked="" type="checkbox"/>	Pregnant/Nursing <input type="checkbox"/>
Bone Loss <input type="checkbox"/>	Type V Refractory Periodontitis; ADA Code 4900 <input type="checkbox"/>	Immunosuppressed <input type="checkbox"/>
Redness/Discoloration <input type="checkbox"/>	Type IV (>6mm); Advanced Periodontitis; ADA Code 4800 <input type="checkbox"/>	Diabetes <input type="checkbox"/>
Halitosis/Malodor <input type="checkbox"/>	Type III (4-6mm); Moderate Periodontitis; ADA Code 4700 <input type="checkbox"/>	Cardiovascular Disease <input checked="" type="checkbox"/>
	Type II (3-4mm); Mild Periodontitis; ADA Code 4600 <input checked="" type="checkbox"/>	Current Smoker <input type="checkbox"/>
	Type I (1-3mm); Gingivitis; ADA Code 4500 <input type="checkbox"/>	
	Good Periodontal Health <input type="checkbox"/>	

Antibiotic Allergies: None Reported

Additional Clinical Information: This patient has a test sample note and test note attached.

Tooth Numbers	3	9	14	19	24	30
Pocket Depths	3mm	3mm	4mm	3mm	2mm	3mm

8

Additional information is available from MyOralDNA.com on:

Interpreting Results	Office Periodontal Protocols	Patient Home Care Steps
Patient Reassessment	Using OralDNA	The Oral-Systemic Connection

Disclaimer: 1. OralDNA is not liable for any outcomes arising from clinician's treatment protocols and decisions. Dentists should consult with a periodontist or patient's physician when infections are advanced or as indicated by patient's medical condition. 2. OralDNA is not responsible for inaccurate test results due to poor sample collection. 3. This test was developed and its performance characteristics determined by OralDNA Labs, Inc. pursuant to CLIA requirements. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

OralDNA Labs, A Service of Access Genetics, LLC, 7400 Flying Cloud Drive, Eden Prairie, MN 55344 855-ORALDNA; Fax: 952-767-0446 www.oraldna.com
Medical Director: Ronald McGlennen, MD

5 Page 2 emphasizes clinical considerations

6 Options to reduce bacterial risk

7 MyPerioPath® can be used to assess response to therapy

8 Links to additional information at MyOralDNA.com